|Akili Interactive Labs Inc., of Boston||Endeavorrx||Game-based digital therapeutic device||Prescription treatment for children with attention-deficit hyperactivity disorder||FDA cleared the digital therapeutic|
|Arch Biopartners Inc., of Toronto||Metablok||LSALT peptide||COVID-19||FDA cleared firm to proceed with phase II trial testing drug in preventing acute lung and kidney injury in patients with COVID-19|
|Edesa Biotech Inc., of Toronto||EB-05||Monoclonal antibody targeting Toll-like receptor 4||Moderate to severe COVID-19||Health Canada approved the start of the phase II/III study|
|Eli Lilly and Co., of Indianapolis||Lyumjev (insulin lispro-aabc)||Rapid-acting insulin||Type 1 and type 2 diabetes||FDA approved the drug|
|Jazz Pharmaceuticals plc, of Dublin, and Pharmamar SA, of Madrid||Zepzelca (lurbinectedin)||Alkylating drug that binds guanine residues within DNA||Metastatic small-cell lung cancer||FDA approved the drug for use in patients with disease progression on or after platinum-based chemotherapy|
|Valeo Pharma Inc., of Montreal||Ethacrynate sodium||Loop diuretic||Congestive heart failure, acute pulmonary edema, renal edema, hepatic cirrhosis with ascites||FDA approved the abbreviated NDA|
For more information about individual companies and/or products, see Cortellis.